• Users Online: 952
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 8  |  Issue : 2  |  Page : 54-60

Coagulation activation in patients with sickle cell disease in Basra, Iraq


1 Hereditary Blood Diseases Center, Missan Health Directorate, Missan, Iraq
2 Department of Pediatrics, College of Medicine, University of Basra; Center for Hereditary Blood Diseases/Basra Health Directorate, Basra, Iraq
3 Center for Hereditary Blood Diseases/Basra Health Directorate, Basra, Iraq

Correspondence Address:
Meaad K Hassan
Department of Pediatrics, College of Medicine, University of Basra, Basra
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joah.joah_19_17

Rights and Permissions

Background: Sickle cell disease (SCD) is considered to be a hypercoagulable state that contributes to the morbidity associated with the disease. Numerous mechanisms can attribute to this hemostatic activation among these patients. Objectives: The study was designed to evaluate changes in hemostatic tests, coagulation inhibitors, fibrinolysis, and phosphatidylserine exposure on red blood cells (RBCs) among patients with SCD during both a vaso-occlusive crisis (VOC) and a steady state. Materials and Methods: This observational study comprised 61 patients with SCD, 2 to 16 years old, and 65 healthy patients. Thrombophilia evaluation included prothrombin time (PT), activated partial thromboplastin time (aPTT), protein C and S, d-dimer and Annexin V expression. The independent t test and one-way analysis of variance test were used for comparison of the mean of different samples. Results: During steady state, patients with SCD had longer PT (14.36 ± 0.98 and 13.32 ± 0.79 s), longer aPTT (31.48 ± 2.52 and 30.11 ± 2.04 s), lower protein C (90.95 ± 20.11 and 98.18 ± 18.42 U/L), lower protein S (60.18 ± 12.96 and 80.8 ± 12.67 U/L), and higher d-dimer (1.19 ± 1.25 and 0.27 ± 0.23 μg/mL) levels than the control group, respectively, P < 0.05. Furthermore, a longer PT (15.02 ± 2.11 s), lower protein C (69.21 ± 16.32 U/L), lower protein S (46.56 ± 9.47 U/L), and higher d-dimer levels (3.44 ± 2.62 μg/mL) were reported during VOC compared to steady state. The mean percentage of RBCs expressing Annexin V was assessed in only 10 patients with SCD and eight in the control group. The mean percentage during a VOC (7.66 ± 3.63) was higher than that during steady state (1.57 ± 0.94) and in the control group (0.41 ± 0.15), P = 0.000. Pearson correlation revealed that d-dimer is significantly associated with hemoglobin, indirect bilirubin, and lactate dehydrogenase, P < 0.05. Conclusion: Patients with SCD, particularly during VOC, undergo significant hematologic alterations that increase their risk of developing coagulation activation-related complications.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5338    
    Printed138    
    Emailed0    
    PDF Downloaded401    
    Comments [Add]    

Recommend this journal